<DOC>
	<DOCNO>NCT02279160</DOCNO>
	<brief_summary>The study conduct placebo-controlled , randomize , 22 week double-blind study include dose titration period . An additional transition period occur patient elect enroll open-label extension study , APD811-007 . Approximately 60 patient PAH enrol .</brief_summary>
	<brief_title>Safety Efficacy APD811 Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Males female age 1875 year , inclusive Symptomatic WHO Group 1 PAH classify one follow subgroup : Idiopathic pulmonary arterial hypertension ( IPAH ) ; Heritable pulmonary arterial hypertension ( HPAH ) ; Drugs toxins induce ; Associated ( APAH ) ; specifically connective tissue disease , HIV infection congenital heart disease Has diagnosis PAH confirm cardiac catheterization Has WHO/NYHA functional class II IV symptomatology Previously diagnose PAH stable oral diseasespecific PAH therapy either ERA and/or agent act nitric oxide pathway , i.e . PDE5 inhibitor soluble guanylate cyclase stimulator . Stable defined change dose within 3 month start Screening duration study Has 6MWT distance 100500 , within 15 % 2 consecutive test do different day Screening Has pulmonary function test ( PFTs ) within 6 month prior start Screening evidence significant parenchymal lung disease Has ventilationperfusion ( V/Q ) lung scan pulmonary angiogram within 5 year prior Screening concomitant follow diagnosis PAH show evidence thromboembolic disease If vasodilator ( include calcium channel blocker ) , digoxin , spironolactone , LArginine supplementation ; patient must stable dose least 1 month prior start Screening Newly diagnose PAH diseasespecific PAH therapy Previous participation clinical study investigational drug , biologic , device within 2 month prior Screening visit Acutely decompensated heart failure within 1 month prior start Screening Systolic blood pressure &lt; 90 mm Hg Screening Evidence history leftsided heart disease and/or clinically significant cardiac disease Use chronic administration ( defined &gt; 30 day ) prostacyclin prostacyclin analogue within 3 month Screening Any previous use prostacyclin prostacyclin analogue stop safety tolerability issue associate pharmacology/mechanism action Other severe acute chronic medical laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make patient inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>